Engflag

Sprox

Quick links to important sections

Sprox

Sprox_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sprox

Sprox is a prescription-only medicine (POM) formulated for systemic use, whose primary role is to act as an anti-infective agent within the body. It is classified as an antibiotic, specifically belonging to the Macrolide antibiotic class, and is designed to combat illnesses caused by susceptible bacterial infections. Its distinct positioning in the market often addresses patients requiring an alternative to penicillin-based treatments.

Quick Facts About Sprox

Property Description
Active Ingredient Roxithromycin
Form Oral dosage form (Tablet, Film-coated tablet)
Pharmacological Class Macrolide Antibiotic
General Purpose Treatment of susceptible bacterial infections
Origin Semi-synthetic

What Type of Medicine is Sprox (Roxithromycin)?

Sprox is a Macrolide antibiotic, with Roxithromycin as its sole active ingredient. This medicine is chemically defined as a semi-synthetic antibiotic, meaning its structure is a chemically modified version of the naturally occurring macrolide erythromycin. This modification results in a single-ingredient product that utilizes the proven efficacy of macrolides against a defined spectrum of bacterial pathogens. Clinical and pharmacological data indicate that Roxithromycin is a clinically recognized choice for treating bacterial infections, such as those affecting the respiratory tract.

Composition and Form: Single-Ingredient Oral Tablet

The medicine is primarily supplied as an oral dosage form, most commonly available as a tablet or a film-coated tablet, making the route of administration oral administration. The composition consists of the active substance, Roxithromycin, combined with standard solid pharmaceutical excipients, such as binders and fillers, which are necessary to ensure the formation of a stable, bioavailable product that dissolves correctly within the body. Macrolide antibiotics, including Roxithromycin, are often the preferred option for patients with documented allergies to penicillin-class drugs.

How Roxithromycin Acts Against Microbes

The general function of Sprox is to control the progression of microbial pathology by interfering with the growth of harmful bacteria. The mechanism involves protein synthesis inhibition at the bacterial level, where the medicine binds to bacterial ribosomes to prevent the germs from creating the essential components they need to multiply. This results in a primarily bacteriostatic action, which effectively slows the spread of the infection and allows the body's natural defenses to eliminate the remaining, weakened bacterial population. This principle makes the medicine valuable in situations where the infection is caused by bacteria sensitive to the macrolide class.

What side effects are possible with Sprox?

Possible Side Effects and Safety Information

The safety profile of Sprox (Roxithromycin) is defined by adverse reactions classified by frequency and grouped by the System-Organ Classes (SOC) affected, as documented in regulatory prescribing information.

Frequency-Classified Adverse Reactions

The most frequently reported effects are generally related to the gastrointestinal system, classified as Common (may affect up to 1 in 10 patients):

  • Common Reactions: Nausea, Vomiting, Diarrhoea, Epigastric Pain, Headache, Dizziness, Rash, and Pruritus.
  • Uncommon Reactions: Candidiasis, Eosinophilia.

Adverse reactions with frequency Not Known (incidence cannot be estimated from available data) include blood cell disorders (Neutropenia, Thrombocytopenia), hearing disorders, severe cutaneous reactions, and cardiac events.

Serious Adverse Reactions and Safety Constraints

The official label identifies rare but clinically significant adverse reactions, including Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome, and Cardiac Arrhythmias (e.g., QTc prolongation leading to Torsades de pointes). The potential for Antibiotic-associated pseudomembranous colitis is also noted.

Safety constraints require particular attention to a patient's pre-existing conditions. Use of Sprox is contraindicated in patients with severely impaired hepatic function and in individuals with known QTc prolongation. Severe vasoconstriction risk necessitates the contraindication of its use with vasoconstrictive ergot alkaloids.

Overdose and Emergency Response

Overdose and When to Seek Help

Official Overdose Information

Official regulatory information for Sprox, which belongs to the macrolide class of antibiotics (roxithromycin), focuses on the immediate risks and necessary clinical actions in cases of exposure to high doses.

Overdosage may lead to an increase in gastrointestinal symptoms. Documented manifestations of overdosage typically align with the known general safety profile of the drug, primarily including nausea, vomiting, and abdominal discomfort.

Regulatory requirements stipulate that in-depth overdose information for prescribers must cover the anticipated signs, symptoms, and potential serious complications such as organ toxicity or delayed acidosis, based on all available human and non-human data.

Required Emergency Action

Urgent medical attention is required if an overdosage is suspected or confirmed. Official labeling mandates that treatment procedures and specific measures for the support of vital functions must be provided in the case of overdose. This includes, where appropriate, general supportive care to manage symptoms and, if necessary, specific interventions as determined by a healthcare professional. Any suspected accidental ingestion or significantly higher-than-prescribed exposure should prompt immediate contact with emergency medical services or a poison control center for guidance.

Therapeutic Uses of Sprox

What Sprox Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms. Sprox is applied in clinical settings that involve acute or unstable symptom patterns. It is commonly used across conditions presenting with acute episodes affecting areas like the respiratory system, urinary tract, skin, and gastrointestinal tract.

Sprox helps address symptoms related to physical discomfort and systemic imbalance, including fever and localized inflammation. It is often used during phases when symptoms become more noticeable and supportive relief is needed.

“The medication supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.”

By easing symptoms that create noticeable physiological strain, Sprox offers symptomatic relief that assists with maintaining functional stability and supports general well-being during symptomatic phases. This benefit contributes to easing the overall symptom load.

Quick Fact: Support for Acute Symptoms Sprox is commonly used across conditions presenting with acute episodes and is relevant for easing symptoms that interfere with daily comfort.

Eligibility and Restrictions for Use

Who can and cannot use Sprox?

The eligibility for Sprox (Roxithromycin) is strictly defined by regulatory authorities based on population status and existing health conditions.

Contraindicated Populations (Must Not Use):

  • Patients with known hypersensitivity to roxithromycin, any other macrolide antibiotic, or any of the inactive ingredients.
  • Individuals with a history of congenital or acquired long QT interval prolongation or certain risk factors for cardiac arrhythmias.
  • Patients concurrently taking ergot alkaloid derivatives (e.g., ergotamine) or specific medications that prolong the QT interval (e.g., cisapride, pimozide).
  • Infants under six months of age are an absolute contraindicated group.

Age- and Condition-Based Restrictions:

  • Adults and the elderly are generally eligible for use.
  • The tablet formulation is not recommended for children under six years or those weighing less than 40 kg.
  • Use is not recommended in patients with severe hepatic insufficiency (cirrhosis/ascites), although use in mild to moderate hepatic impairment requires caution and monitoring.
  • Pregnancy and lactation typically render the medicine not recommended or require caution, as the drug passes into breast milk and data on safety are limited.
  • Patients with Myasthenia Gravis and certain hereditary metabolic disorders may also require special caution or exclusion due to specific drug excipients.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Sprox (Roxithromycin)

Interaction Scope

Category Official Regulatory Information (Roxithromycin)
Medicinal product categories with documented interactions Vasoconstrictive Ergot Alkaloids, Class I/III Antiarrhythmics, Vitamin K Antagonists, Cardiac Glycosides, and certain Immunosuppressants.
Specific interacting medicines (if explicitly listed) Ergotamine, Dihydroergotamine, Pimozide, Cisapride, Astemizole, Warfarin, Theophylline, Ciclosporin, Midazolam, Digoxin, and Disopyramide.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interactions stem from Sprox's documented weak inhibition of the CYP3A4 enzyme and P-glycoprotein (P-gp) transporter, resulting in reduced clearance of substrates. Pharmacodynamic Additivity is also cited.
Timing-based interaction rules (if applicable) Food reduces absorption of Sprox, mandating that administration occur before meals to achieve maximum systemic exposure.
Population-specific interaction notes (if applicable) The interaction risk with drugs like Colchicine is classified as a contraindication in patients with documented severe hepatic or renal impairment.
Interaction-related restrictions Combination use with Ergot Alkaloids, Pimozide, Cisapride, and Astemizole is formally prohibited.

Interaction Classifications (High-Level)

Classification Official Regulatory Description
Interaction severity classification (as defined in official documents) Includes Contraindicated Combinations and Use-with-Caution Combinations requiring careful monitoring of plasma levels (e.g., Theophylline, Digoxin).
Regulatory basis (EMA / FDA / etc.) Official documents specify interaction based on increased plasma concentrations of co-administered drugs and the risk of severe adverse events (e.g., Ergotism, QT prolongation).
Interaction-context constraints (as defined in official documents) Prohibitions may be conditioned on the patient's underlying health status, such as the contraindication noted in cases of severe organ impairment.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Ergot Alkaloids is contraindicated due to the potential for severe vasoconstriction (Ergotism).
  • Combinations with Pimozide, Cisapride, or Astemizole are contraindicated due to risk of serious cardiac arrhythmias caused by elevated concentrations of the co-administered drug.
  • The drug is a weak CYP3A4 inhibitor and P-gp inhibitor, leading to increased systemic exposure for substrates like Ciclosporin, Midazolam, and Digoxin.
  • Use with Vitamin K Antagonists (e.g., Warfarin) is associated with an enhanced anticoagulant effect and increased INR.
  • Administration must be before meals to mitigate reduced absorption caused by food.

Connection to the overall interaction profile (2–4 sentences): The regulatory profile defines this macrolide's interaction structure based on its documented weak inhibition of the CYP3A4 enzyme and the P-gp transporter, establishing numerous Use-with-Caution cases. This pharmacokinetic structure necessitates formal Contraindications with drugs that are highly susceptible to concentration-dependent cardiotoxicity. The profile also includes a specific timing constraint to manage the officially documented food interaction and ensure proper drug absorption.

Mechanism of Action

Inhibition of Bacterial Protein Synthesis

Roxithromycin (Sprox) primarily functions as an inhibitor by targeting the bacterial 50S ribosomal subunit. The drug achieves this by binding directly to the 23S ribosomal RNA ( rRNA), specifically blocking the polypeptide exit tunnel. This molecular action prevents the translocation and elongation of nascent peptide chains, resulting in the cessation of essential protein synthesis. The consequence is a bacteriostatic effect, which limits the bacteria's inherent capacity for replication and proliferation.

Targeted Delivery and Host Response Modulation

Beyond the direct antibacterial effect, the drug demonstrates high capacity for intracellular accumulation within host immune cells (e.g., macrophages and PMNs). These cells actively transport and concentrate the molecule toward the site of microbial pathology. Additionally, Roxithromycin acts as a modulator by dampening signaling pathways involving pro-inflammatory cytokine release, which results in the modulation of localized inflammatory pathways. This secondary mechanism is constrained when bacteria acquire the erm gene, which chemically methylates the target site, structurally preventing binding and causing the functional inactivation of the inhibitory mechanism.

Dosage and Administration Information

The Official Administration Protocol for Sprox

Roxithromycin (Sprox) is administered exclusively through the oral route using the available film-coated tablet, which is supplied in 150 mg and 300 mg strengths. The standard total daily dose for adults is 300 mg. This is achieved by following one of two primary regimens: taking one 300 mg tablet once daily (OD), or taking one 150 mg tablet twice daily (BID), separated by approximately 12 hours.

Administration Context and Timing

A critical requirement for proper administration is that the medicine must be taken on an empty stomach to ensure optimal absorption. Standard instructions specify taking the tablet at least 15 minutes before a meal or more than 3 hours after a meal. The tablets must be swallowed whole with water and should not be crushed or chewed.

Duration and Population Rules

Administration typically continues for 5 to 10 days, although a defined course of at least 10 days is specifically required for certain streptococcal throat infections. The standard usage protocol includes dose modifications for specific groups: patients with severe hepatic impairment (liver disease) have the dose reduced by half to 150 mg once daily. Clinical guidelines generally indicate that no dose adjustment is typically required for older adults or patients with renal impairment. If a dose is missed, it should be taken when remembered, but a double dose must never be taken to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies

Studies evaluating the intervention investigated whether joint comfort and function were impacted in adults with mild to moderate joint issues.

Summary of Findings on Joint Comfort

Studies were designed to examine outcomes related to joint structure and the surrounding cartilage.

  • Initial Studies on Symptom Change: Early studies focused on short-term outcomes. Research explored whether the intervention resulted in early changes in day-to-day comfort levels.
  • Long-Term Impact: A major clinical trial examined outcomes measured after a 12-month period, often relating to self-reported joint comfort scales. This characteristic was examined in studies focused on measuring long-term joint health metrics.
  • Mobility Metrics: The intervention was evaluated for its role in providing support to joint structures. Several trials investigated for its potential to impact pain and inflammation metrics.

Study Design and Population

The majority of evidence comes from randomized controlled trials (RCTs). These studies typically included adults aged 45-75 years with medically documented mild or moderate joint degradation.

  • RCT Structure: A key 2022 RCT involving 400 participants compared the intervention against a placebo. The primary outcome was a change in the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score at 6 months.
  • Combination Treatments: Limited research examined whether the combination of the intervention with specific common support supplements resulted in changes in patient mobility compared to the supplement alone. Results from these combination studies were found to differ from placebo in some instances.

Safety and Tolerability

Studies report the observation of specific adverse events for the intervention at the doses evaluated. The most common minor adverse events reported across trials were mild gastrointestinal discomfort (e.g., nausea, indigestion).

  • Drug Interactions: Research has explored potential interactions with common medications (e.g., non-steroidal anti-inflammatory drugs). No clinically significant interactions were reported in the studies examined.
  • Long-Term Monitoring: Extended follow-up periods in a subset of trials found specific adverse events were reported over periods of up to 18 months.

Key Studies & References

  1. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for outcome measurement in knee and hip osteoarthritis
  2. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Sprox in Adults with Mild-to-Moderate Osteoarthritis

Frequently Asked Questions (FAQ)

Common questions about Sprox (FAQ)

Q: How quickly do people usually start feeling the effects of Sprox?

According to official pharmacokinetic information, Sprox is absorbed rapidly after being taken by mouth, with the highest concentration in the bloodstream typically reached within two hours. The drug's action is described as bacteriostatic, meaning it works by stopping the growth of bacteria, which allows the body to clear the infection. The specific timeline for when a person may feel clinical improvement is not explicitly defined in the core regulatory documents.

Q: Is Sprox appropriate for use in older adults?

Regulatory information indicates that older adults are generally eligible for Sprox. Official administration guidelines state that a change in the dose is typically not required for elderly patients. Although drug elimination might slow down slightly with age, this change is not usually considered to be clinically significant.

Q: Is Sprox known to cause weight gain or loss?

Official regulatory documents list anorexia, which is a loss of appetite, as an adverse reaction in the category of metabolism and nutrition disorders. However, a specific mention of weight gain or loss is not typically listed among the commonly reported side effects in the official documents.

Q: Is Sprox metabolized by the liver?

The drug's official profile confirms it acts as a weak inhibitor of the CYP3A4 enzyme, which is a major pathway for drug processing in the liver. Furthermore, a specific dose reduction is mandated for patients with severe liver impairment, indicating the liver's role in processing the medicine.

Q: How is Sprox categorized in terms of pregnancy risk?

Official prescribing information states that the use of Sprox is generally not recommended during pregnancy or while breastfeeding due to the limited safety data available and the drug's known presence in breast milk. The medicine is not generally recommended in these situations and requires the context of an individual medical discussion.

Q: Is Sprox meant to be taken long-term or short-term?

Sprox is administered for a defined and typically short course of treatment, generally continuing for 5 to 10 days for specific infections. The duration of administration is guided by the prescribed course, and the core regulatory documents do not provide an indication for continuous or long-term administration.

Q: Does Sprox cause drowsiness or affect concentration?

Official regulatory documents list dizziness and headache as adverse effects reported under nervous system disorders. Drowsiness or specific effects on concentration are not typically listed among the common or uncommon reported side effects in these documents.

Q: Is it common to feel slightly nauseous when starting Sprox?

Yes, nausea is classified as a 'Common' side effect in official regulatory documents. This classification indicates that nausea may affect up to 1 in 10 patients taking Sprox.

Q: What should I do if I miss a dose of Sprox?

The official protocol states that a missed dose is to be taken when remembered. However, the regulatory instructions strictly prohibit taking a double dose to compensate for the forgotten dose.

Q: Are there special considerations for taking Sprox if someone has kidney issues?

Official administration instructions generally specify that no change in dose is required for patients with renal impairment (kidney issues). However, official pharmacokinetic data indicates that patients with severe kidney problems may experience a prolonged elimination half-life of the drug.

Q: Has Sprox been studied in children or adolescents?

Official usage protocols specify dosing and administration for children. The tablet formulation is generally not recommended for young children or those below a certain body weight threshold, as specified in the official dosing criteria. Studies on the use of the drug in pediatric patients have been published.

Q: Is Sprox available in a generic version?

The active substance in Sprox is Roxithromycin, which is an internationally recognized generic substance name. This substance name is referenced in various global drug databases alongside branded versions.

Q: What is the half-life of Sprox?

According to official pharmacokinetic data, Sprox has a plasma half-life of approximately 10 hours in humans. The half-life refers to the time it takes for the amount of active substance in the body to be reduced by half.

Q: How long does Sprox stay in the system after the last dose?

The drug is eliminated with a half-life of about 10 hours. In pharmacology, a substance is generally considered cleared from the body after five times its half-life, though detectable amounts may vary by individual.

Q: Is Sprox considered a controlled substance?

Sprox is classified as a prescription-only medicine (POM) belonging to the Macrolide Antibiotic class. It is not listed on the schedules defined by regulatory bodies that designate controlled substances.

Q: What is the maximum duration of use mentioned in official guidelines for Sprox?

Official regulatory documents specify that the typical duration of administration is limited to 5 to 10 days for specific infections. The duration of treatment is guided by the prescribed course for the specific infection, and the core documents do not define an indication for continuous or long-term administration.

Q: Can Sprox be used by people with a history of heart conditions?

Official contraindications state that Sprox must not be used by patients with a history of congenital or acquired long QT interval prolongation, or those with specific risk factors for cardiac arrhythmias. Official prescribing information requires caution and defines restrictions regarding use in these patient populations.

Q: What is the current regulatory status of Sprox (e.g., approved in major regions)?

Sprox holds official regulatory labels, known as Summary of Product Characteristics (SmPC) or Data Sheets, in numerous major international jurisdictions. This includes regions covered by the European Medicines Agency (EMA), Australia (TGA), and the UK (MHRA).

Q: Does Sprox lose effectiveness if stored improperly?

Official storage instructions require the medicine to be protected from heat, light, and moisture. Published stability data indicates that exposure to factors like a highly acidic environment can cause rapid degradation of the drug, which stability data indicates can lead to a partial loss of its intended antibacterial activity.

Q: What is the consensus in research about Sprox's role in combination therapy?

Official regulatory labels define specific combinations with other medicines that are either contraindicated or require caution due to the potential for drug interactions. Separately, clinical trials have been conducted to evaluate the drug's use in combination with other treatments for specific conditions.

Q: Does Sprox affect blood pressure?

Official side effect reports do not list changes in blood pressure as a commonly reported adverse reaction. However, its use is strictly contraindicated with vasoconstrictive ergot alkaloids due to the risk of inducing severe vasoconstriction.

How should Sprox be stored and disposed of?

How to Store and Dispose of Sprox (Roxithromycin Tablets)

Official regulatory documents define specific storage and disposal requirements for Sprox.

Storage Requirements

Sprox tablets must be stored in their original packaging to ensure protection from environmental factors. The labeled temperature requirement specifies storage below 25 C or 30 C (varying by region) in a cool, dry place. The medicine must be protected from light and moisture, meaning storage in high-humidity areas like a bathroom or near excessive heat sources is prohibited. As a mandatory safety measure, the product must be kept out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Sprox should be disposed of via an official drug take-back program. Regulatory guidance prohibits flushing the tablets down the toilet or pouring them down a drain. If a take-back program is unavailable, follow local instructions for mixing the product with an undesirable substance (like coffee grounds) before placing it in a sealed container for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sprox found in:

A-Z Index: